

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vigovita Life Sciences Co., Ltd.

蘇州旺山旺水生物醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2630)

**VOLUNTARY ANNOUNCEMENT
ENTERING INTO LICENSE AGREEMENT WITH
SIMCERE PHARMACEUTICAL FOR NEW INDICATIONS OF
DEUREMIDEVIR HYDROBROMIDE (VV116)**

This announcement is made by Vigovita Life Sciences Co., Ltd. (蘇州旺山旺水生物醫藥股份有限公司) (the “**Company**” or “**Vigovita**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Company has entered into a license agreement (the “**Agreement**”) with Simcere Pharmaceutical Group Limited (“**Simcere Pharmaceutical**”) for new indications of VV116. Pursuant to the Agreement, the Company will grant Simcere Pharmaceutical exclusive license rights for VV116 in the Greater China region for the indications of treating infections caused by respiratory syncytial virus (“**RSV**”) and human metapneumovirus (“**HMPV**”). By leveraging the respective strengths of Vigovita and Simcere Pharmaceutical in research and development, production, and commercialization, the collaboration between the two major industry players will accelerate the clinical development and commercialization of VV116, thereby benefiting a greater number of patients.

ABOUT VV116

VV116 is a novel oral nucleoside prodrug that received conditional marketing approval from the National Medical Products Administration in January 2023 and the conditional marketing approval was converted to regular approval in January 2025 for the treatment of mild to moderate COVID-19 infections. Current research indicates that VV116 exhibits broad-spectrum antiviral activity and demonstrates potent inhibitory effects against multiple RNA viruses, including RSV.

In RSV treatment, a Phase II clinical trial of VV116 dry suspension for the treatment of infants and young children infected with RSV has been completed. Based on the positive results from this clinical trial, VV116 received the Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Preclinical studies indicate that VV116 exhibits substantial antiviral efficacy in both *in vitro* and animal models, and improves pathological lung damage. Clinical pharmacokinetic studies indicate that VV116 exhibits good oral absorption and linear pharmacokinetic properties, with no significant impact of infant formula on the bioavailability of its primary metabolite. In clinical trials, VV116 demonstrated a favorable overall safety profile, with no serious adverse events observed.

ABOUT SIMCERE PHARMACEUTICAL

Simcere Pharmaceutical, a listed company on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 2096.HK), is an innovation and R&D-driven pharmaceutical company and has established a “State Key Laboratory of Neurology and Oncology Drug Development”. Simcere Pharmaceutical focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, Simcere Pharmaceutical has established strategic cooperation partnerships with many innovative companies and research institutes.

ABOUT THE COMPANY

Established in 2013, Vigonvita is an innovation-driven biopharmaceutical company committed to improving patients’ health and quality of life. The Company is dedicated to the development of novel drugs in the fields of neuropsychiatry, reproductive health and viral infection. Vigonvita has established an integrated functional and fully internally controlled system covering the whole industrial chain from lead discovery for innovative drugs, druggability evaluation, preclinical and clinical research to manufacturing and commercialization, thereby enabling the rapid and efficient transformation of candidate drugs from laboratory research to clinical application.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, December 3, 2025

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.